Medical Oncology Research

The Medical Oncology Clinical Trials Unit was established in 1985 and is integrated within the Medical Oncology department. We value multidisciplinary and interdepartmental research. Our research portfolio includes:

Phase I, II and III interventional clinical trials
Observational studies
Studies inclusive of a broad range of cancer types
Studies on the assessment and management of cancer
Studies on the psychosocial and survivorship care of people with cancer
Studies to improve the health care delivery of people with cancer

We support industry and investigator-led studies. We collaborate with Cancer Cooperative Groups, universities, and pharmaceutical companies to identify and conduct important research studies that will improve the lives of people with cancer.

Our team are experienced, enthusiastic, and diligent in their research activities, and share knowledge from their diverse backgrounds in nursing, science, and ethics to improve the unit. We provide a constant point of contact for sponsored studies. Our role in each study is determined by individual trial requirements and may include assistance with ethics submissions, recruitment, participant visits and data management.

All staff participate in professional development activities, such as attendance at educational events and conferences, to consolidate and improve their research knowledge and skills.

Selected Grants

Amount awarded	Grant and project details
$2,000,000	Griffith Contribution, 2021-2024 A randomised, controlled trial evaluating the effect of exercise during chemotherapy for ovarian cancer on survival and health resource use Investigator: Beale P
$1,600,000	NHMRC, 2020-2025 Improving long term health for cancer survivors Investigator: Vardy J
$1,100,000	NHMRC, 2019-2024 Phase III study of the impact of a physical activity program on disease-free survival for early colon cancer, “CHALLENGE”: Colon Health and Life Long Exercise ChaNGE Investigators: Vardy J, Dhillon H, Courneya K, Booth C, O’Callaghan C, Zalcberg J, Burge M
$686,674	Medical Research Future Fund (MRFF), 2020-2023 HyNOVA - A randomised study comparing Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer Investigator: Beale P
$600,000	NHMRC, 2023-2026 Intraperitoneal bevacizumab for recurrent malignant ascites (REZOLV3R) Investigator: Stockler M
$494,132	NHMRC, 2023-2026 ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer Investigators: Mileshkin L, Lee YC, Friedlander M, Brand A, Ledermann J, Davis A, Beale P, Coward J, Viney R
$300,000	Dust Diseases Board Research Grant, 2020-2023 A novel 3D model for drug screening in mesothelioma Investigator: Linton A
$300,000	National Foundation for Australia-China Relations, 2023-2024 Advancing Cancer Survivorship Through Partnership Between Australia and Greater China (The AC2 Project) Investigator: Vardy J
$144,188	NHMRC, 2023 Evaluating the time toxicity of cancer treatments in patients with advanced solid-organ malignancy Investigator: Stevens S
$116,320	Sydney Cancer Partners, 2023 Evaluating the time toxicity of chemotherapy for metastatic colorectal cancer using patient survey data: a prospective feasibility study Investigators: Stephens S, Vardy J

Previous Grants

Amount awarded	Grant and project details
$149,800	Faculty of Medicine and Health/Professor Martin Tattersall Early Career Researcher Award Scheme, 2022 A phase 2 feasibility study evaluating a structured telehealth Lifestyle intervention (Exercise And Diet) for early-stage breast cancer survivors (LEAD-4-BCs) undergoing neo-adjuvant/adjuvant chemotherapy. Investigators: Tan C, Vardy J
$15,000	Concord Cancer Centre, 2020-2022 Prehabilitation for gastrointestinal cancer surgery. (PREHAB-GI). Investigators: Raso K-L, Vardy J, Khatri S, Becerril-Martinez G, le Page P, Lin Y, Wildbore C.
$900	Australian Gastro-Intestinal Trials Group (AGITG), 2022 AGITG Travel Scholarship 2022 Annual Scientific Meeting. Awardees: Quinn C, Thomas S, Hooshmand E.

Our Publications

2023

Agar MR, Nowak AK, Hovey EJ, Barnes EH, Simes J, Vardy JL, Wheeler HR, Kong BY, Leonard R, Hall M, Tim E, Spyridopoulos D, Sim HW, Lwin Z, Dowling A, Harrup R, Jennens R, Kichenadasse G, Dunlop T, Gzell C, Koh ES. Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study. BMJ Support Palliat Care. 2023 Sep;13(3):354-362. doi: 10.1136/spcare-2022-004119. Epub 2023 Feb 17.

Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, Chadban SJ, Bowen DG, Chen AC, Damian DL. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N Engl J Med. 2023 Mar 2;388(9):804-812. doi: 10.1056/NEJMoa2203086.

Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080.

Bui KT, Li Z, Dhillon HM, Kiely BE, Blinman P. Scanxiety Conversations on Twitter: Observational Study. JMIR Cancer. 2023 Apr 19;9:e43609. doi: 10.2196/43609.

Butow P, Faris MM, Shaw J, Kelly P, He S, Harris M, Cuddy J, Masya L, Geerligs L, Kelly B, Girgis A, Rankin N, Beale P, Hack TF, Kirsten L, Dhillon H, Grimison P, Viney R, Clayton JM, Schlub T; ADAPT Program Group; Shepherd HL. Effect of core versus enhanced implementation strategies on adherence to a clinical pathway for managing anxiety and depression in cancer patients in routine care: a cluster randomised controlled trial. Implement Sci. 2023 May 22;18(1):18. doi: 10.1186/s13012-023-01269-0.

Butow P, Havard PE, Butt Z, Juraskova I, Sharpe L, Dhillon H, Beatty L, Beale P, Cigolini M, Kelly B, Chan RJ, Kirsten L, Best MC, Shaw J. Stakeholder perspectives on the impact of COVID-19 on oncology services: a qualitative study. Support Care Cancer. 2023 Jul 24;31(8):491. doi: 10.1007/s00520-023-07916-y.

Campbell I, Wetzig N, Ung O, Espinoza D, Farshid G, Collins J, Kollias J, Gebski V, Mister R, Simes RJ, Stockler MR, Gill G. 10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection. Breast. 2023 Aug;70:70-75. doi: 10.1016/j.breast.2023.06.009. Epub 2023 Jun 23.

Campbell R, King MT, Stockler MR, Lee YC, Roncolato FT, Friedlander ML. Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice. Patient Relat Outcome Meas. 2023 May 8;14:111-126. doi: 10.2147/PROM.S297301.

Conduit C, Lewin J, Weickhardt A, Lynam J, Wong S, Grimison P, Sengupta S, Pranavan G, Parnis F, Bastick P, Campbell D, Hansen AR, Leonard M, McJannett M, Stockler MR, Gibbs P, Toner G, Davis ID, Tran B, Kuchel A. Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncol Pract. 2023 Nov;19(11):973-980. doi: 10.1200/OP.23.00191. Epub 2023 Jun 16.

Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, Gedye C, Mallesara G, Guminski A, Lee A, Stockler MR, Hickey A, Eu P, Joshua AM, Crumbaker M, Nguyen A. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 2023 Mar 1;15:17588359231156392. doi: 10.1177/17588359231156392.

Fardell JE, Irwin CM, Vardy JL, Bell ML. Anxiety, depression, and concentration in cancer survivors: National Health and Nutrition Examination Survey results. Support Care Cancer. 2023 Apr 15;31(5):272. doi: 10.1007/s00520-023-07710-w.

Fardell JE, Tan SYC, Kerin-Ayres K, Dhillon HM, Vardy JL. Symptom Clusters in Survivorship and Their Impact on Ability to Work among Cancer Survivors. Cancers (Basel). 2023 Oct 24;15(21):5119. doi: 10.3390/cancers15215119.

Fardell JE, Walker A, Chan RJ, Vardy JL. Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts? JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad026. doi: 10.1093/jncics/pkad026.

Kasherman L, Yoon WH, Tan SYC, Malalasekera A, Shaw J, Vardy J. Cancer survivorship programs for patients from culturally and linguistically diverse (CALD) backgrounds: a scoping review. J Cancer Surviv. 2023 Aug 12. doi: 10.1007/s11764-023-01442-w. Epub ahead of print.

Lee J, Currow D, Lovell M, Phillips JL, McLachlan A, Ritchie M, Brown L, Fazekas B, Aggarwal R, Seah D, Sheehan C, Chye R, Noble B, McCaffrey N, Aggarwal G, George R, Kow M, Ayoub C, Linton A, Sanderson C, Mittal D, Rao A, Prael G, Urban K, Vandersman P, Agar M. Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study. BMJ Open. 2023 Feb 21;13(2):e066125. doi: 10.1136/bmjopen-2022-066125.

Livingstone A, Howard K, Menzies AM, Long GV, Stockler MR, Morton RL. Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment. Patient. 2023 Sep;16(5):497-513. doi: 10.1007/s40271-023-00635-w. Epub 2023 Jun 23.

Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, Bradshaw N, Lee YC, Diamante K, Fyles AW, Small W Jr, Gaffney DK, Khaw P, Brooks S, Thompson JS, Huh WK, Mathews CA, Buck M, Suder A, Lad TE, Barani IJ, Holschneider CH, Van Dyk S, Quinn M, Rischin D, Monk BJ, Stockler MR. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 May;24(5):468-482. doi: 10.1016/S1470-2045(23)00147-X. Epub 2023 Apr 17.

Morris JN, Crawford-Williams F, Koczwara B, Chan RJ, Vardy J, Lisy K, Iddawela M, Mackay G, Jefford M. Current landscape of cancer survivorship research in Australia. Asia Pac J Clin Oncol. 2023 Oct;19(5):e305-e313. doi: 10.1111/ajco.13914. Epub 2023 Jan 19.

Naher SK, Mercieca-Bebber R, Siu D, Grimison P, Stockler MR. Prognostic value of patient reported outcomes in advanced gastro-oesophageal cancer: a systematic review. Intern Med J. 2023 Nov;53(11):1946-1955. doi: 10.1111/imj.16209. Epub 2023 Aug 22.

Nahm SH, Martin AJ, Clayton JM, Grimison P, Moth EB, Pavlakis N, Sjoquist K, Smith-Uffen MES, Tognela A, Vasista A, Stockler MR, Kiely BE. Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad094. doi: 10.1093/jncics/pkad094.

Nahm SH, Stockler MR, Kiely BE. Voluntary assisted dying: estimating life expectancy to determine eligibility. Med J Aust. 2023 Jan 16;218(1):48. doi: 10.5694/mja2.51790. Epub 2022 Nov 24.

Obeid LA, Dhillon HM, Tan SY, Vardy JL. Is there a need for change in cancer survivorship care? A qualitative exploration of survivor experiences and needs at the Sydney Cancer Survivorship Centre Clinic. Support Care Cancer. 2023 Oct 18;31(12):642. doi: 10.1007/s00520-023-08102-w.

Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). J Nucl Med. 2023 Jan;64(1):69-74. doi: 10.2967/jnumed.122.264104. Epub 2022 Jun 23.

Raso KL, Suen M, Turner J, Khatri S, Lin Y, Wildbore C, Becerril-Martinez G, Le Page P, Tan SY, Egger S, Vardy J. Prehabilitation Before Gastrointestinal Cancer Surgery: Protocol for an Implementation Study. JMIR Res Protoc. 2023 Mar 27;12:e41101. doi: 10.2196/41101.

Shafiei M, Galettis P, Beale P, Reuter SE, Martin JH, McLachlan AJ, Blinman P. Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study. Cancer Chemother Pharmacol. 2023 Aug;92(2):135-139. doi: 10.1007/s00280-023-04552-5. Epub 2023 Jun 23.

Shafiei M, Mahmood A, Beale P, Galettis P, Martin J, McLachlan AJ, Blinman P. Dried Blood Spot Sampling in the Monitoring of Anticancer Therapy for Solid Tumors: A Systematic Review. Ther Drug Monit. 2023 Jun 1;45(3):293-305. doi: 10.1097/FTD.0000000000001082. Epub 2023 Feb 3.

Sjoquist KM, Martin A, Pavlakis N, Goldstein D, Tsobanis E, Moses D, Maher R, Hague W, Gebski V, Stockler MR, Simes RJ; Australasian Gastro-Intestinal Trials Group (AGITG). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. J Cancer Res Clin Oncol. 2023 Jul;149(8):4959-4965. doi: 10.1007/s00432-022-04404-4. Epub 2022 Oct 31.

Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3.

Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT). The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization. Int J Gynecol Cancer. 2023 Apr 3;33(4):628-630. doi: 10.1136/ijgc-2022-004236.

Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT). The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization. J Gynecol Oncol. 2023 Mar;34(2):e33. doi: 10.3802/jgo.2023.34.e33.

Teng C, Chiarovano E, Tighe D, Bui KT, Venkatesha, Blinman PL, MacDougall HG, Vardy JL. Exploring assessment of balance using virtual reality in patients at risk of chemotherapy-induced peripheral neuropathy. Intern Med J. 2023 Aug;53(8):1356-1365. doi: 10.1111/imj.15861. Epub 2022 Sep 14.

Yenson VM, Amgarth-Duff I, Brown L, Caperchione CM, Clark K, Cross A, Good P, Landers A, Luckett T, Philip J, Steer C, Vardy JL, Wong AK, Agar MR. Defining research priorities and needs in cancer symptoms for adults diagnosed with cancer: an Australian/New Zealand modified Delphi study. Support Care Cancer. 2023 Jul 3;31(7):436. doi: 10.1007/s00520-023-07889-y.

Yung A, Kay J, Beale P, Gibson KA, Shaw T. Computer-Based Decision Tools for Shared Therapeutic Decision-making in Oncology: Systematic Review. JMIR Cancer. 2021 Oct 26;7(4):e31616. doi: 10.2196/31616.

2022

Bui, K.T., Kiely, B.E., Dhillon, H.M., Brown, C., Xu, K., Shafiei, M. & Blinman, P. Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey. Support Care Cancer 2022; 30(1), 1-9. doi: 10.1007/s00520-021-06454-9.

Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. PMID: 36261050.

Campbell R, Costa DSJ, Stockler MR, Lee YC, Ledermann JA, Berton D, Sehouli J, Roncolato FT, Connell RO, Okamoto A, Bryce J, Oza AM, Avall-Lundqvist E, Berek JS, Lanceley A, Joly F, Hilpert F, Feeney A, Kaminsky MC, Diamante K, Friedlander ML, King MT; GCIG Symptom Benefit Group. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecol Oncol. 2022 Aug;166(2):254-262. doi: 10.1016/j.ygyno.2022.05.024. Epub 2022 Jun 17. PMID: 35718565.

Conduit C, Mak B, Qu W, Lulio JD, Burder R, Bressel M, Cusick T, Dhillon HM, Lourenço RA, Underhill C, Torres J, Crumbaker M, Honeyball F, Linton A, Allen R, Davis ID, Clark SJ, Horvath LG, Mahon KL. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol). Ther Adv Med Oncol. 2022 Apr 18;14:17588359221092486. doi: 10.1177/17588359221092486. eCollection 2022.

Hayne D, Grummet J, Espinoza D, McCombie SP, Chalasani V, Ford KS, Frydenberg M, Gilling P, Gordon B, Hawks C, Konstantatos A, Martin AJ, Nixon A, O'Brien C, Patel MI, Sengupta S, Shahbaz S, Subramaniam S, Williams S, Woo HH, Stockler MR, Davis ID, Buchan N; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). 'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501). BJU Int. 2022 May;129(5):591-600. doi: 10.1111/bju.15552. Epub 2021 Jul 30. PMID: 34273231; PMCID: PMC9291594.

Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML; GCIG Symptom Benefit Group. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Int J Gynecol Cancer. 2022 Jun 6;32(6):761-768. doi: 10.1136/ijgc-2021-003142. PMID: 35086926; PMCID: PMC9185817.

Lovell MR, Phillips JL, Luckett T, Lam L, Boyle FM, Davidson PM, Cheah SL, McCaffrey N, Currow DC, Shaw T, Hosie A, Koczwara B, Clarke S, Lee J, Stockler MR, Sheehan C, Spruijt O, Allsopp K, Clinch A, Clark K, Read A, Agar M. Effect of Cancer Pain Guideline Implementation on Pain Outcomes Among Adult Outpatients With Cancer-Related Pain: A Stepped Wedge Cluster Randomized Trial. JAMA Netw Open. 2022 Feb 1;5(2):e220060. doi: 10.1001/jamanetworkopen.2022.0060. PMID: 35188554; PMCID: PMC8861847.

Mak B, Lin HM, Duong T, Mahon KL, Joshua AM, Stockler MR, Gurney H, Parnis F, Zhang A, Scheinberg T, Wittert G, Butler LM, Sullivan D, Hoy AJ, Meikle PJ, Horvath LG. Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin. Cancers (Basel). 2022 Sep 30;14(19):4792. doi: 10.3390/cancers14194792. PMID: 36230715; PMCID: PMC9563053.

Mak B, Lin HM, Kwan EM, Fettke H, Tran B, Davis ID, Mahon K, Stockler MR, Briscoe K, Marx G, Zhang A, Crumbaker M, Tan W, Huynh K, Meikle TG, Mellett NA, Hoy AJ, Du P, Yu J, Jia S, Joshua AM, Waugh DJ, Butler LM, Kohli M, Meikle PJ, Azad AA, Horvath LG. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Med. 2022 Mar 25;20(1):112. doi: 10.1186/s12916-022-02298-0. PMID: 35331214; PMCID: PMC8953070.

Moth EB, Stockler MR, Kiely BE. Estimating prognosis in advanced cancer: Time to embrace uncertainty. J Geriatr Oncol. 2022 Apr;13(3):389-390. doi: 10.1016/j.jgo.2021.11.014. Epub 2021 Dec 9. PMID: 34896060.

Nahm SH, Stockler MR, Kiely BE. Voluntary assisted dying: estimating life expectancy to determine eligibility. Med J Aust. 2022 Aug 15;217(4):178-179. doi: 10.5694/mja2.51648. Epub 2022 Jul 24. PMID: 35871393; PMCID: PMC9545219.

Nahm SH, Stockler MR, Martin AJ, Grimison P, Fox P, Zielinski R, Hawson GA, Tattersall MH, Kiely BE. Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals. Support Care Cancer. 2022 Sep;30(9):7763-7772. doi: 10.1007/s00520-022-07167-3. Epub 2022 Jun 15. PMID: 35701634; PMCID: PMC9385826.

Oza B, Eisen T, Frangou E, Stewart GD, Bex A, Ritchie AWS, Kaplan R, Smith B, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Joniau S, Hancock B, Hermann GG, Bellmunt J, Parmar MKB, Royston P, Meade A. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. J Clin Oncol. 2022 Jun 1;40(16):1772-1782. doi: 10.1200/JCO.21.01090. Epub 2022 Feb 25. PMID: 35213214; PMCID: PMC9148696.

Shi H, Rath EM, Lin RCY, Sarun KH, Clarke CJ, McCaughan BC, Ke H, Linton A, Lee K, Klebe S, Maitz J, Song K, Wang Y, Kao S, Cheng YY. 3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies.Front Oncol. 2022 Aug 26;12:973576. doi: 10.3389/fonc.2022.973576. eCollection 2022.

Sjoquist KM, Martin A, Pavlakis N, Goldstein D, Tsobanis E, Moses D, Maher R, Hague W, Gebski V, Stockler MR, Simes RJ; Australasian Gastro-Intestinal Trials Group (AGITG). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. J Cancer Res Clin Oncol. 2022 Oct 31. doi: 10.1007/s00432-022-04404-4. Epub ahead of print. PMID: 36310299.

Smith D, Robledo KP, Yip S, Cummins MM, Kok PS, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Spurdle AB, Andrews J, Stockler MR, Mileshkin L, Antill Y; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers (Basel). 2022 Dec 30;15(1):254. doi: 10.3390/cancers15010254. PMID: 36612250; PMCID: PMC9818816.

Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. J Clin Oncol. 2022 Mar 10;40(8):837-846. doi: 10.1200/JCO.21.00941. Epub 2021 Dec 20. PMID: 34928708; PMCID: PMC8906451.

Stockler MR, Martin AJ, Dhillon HM, Davis ID, Sweeney CJ. Reply to L. Marandino et al. J Clin Oncol. 2022 Jul 1;40(19):2176-2177. doi: 10.1200/JCO.22.00497. Epub 2022 Apr 21. PMID: 35446681.

Teng C, Egger S, Blinman PL, Vardy JL. Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial. Support Care Cancer. 2022;31(1):52. Published 2022 Dec 17. doi:10.1007/s00520-022-07463-y

Teng C, Vardy JL. "POLAR-izing" Findings from trials of neuroprotection for oxaliplatin neuropathy. JNCI Cancer Spectrum. 2022 Dec 6(6): pakc076 doi: 10.1093/jncics/pkac076

Teng C, Venkatesha, Blinman PL, Vardy JL. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors. J Natl Compr Canc Netw. 2022;20(12):1308-1315. doi:10.6004/jnccn.2022.7050

Teng, C., Chiarovano, E., Tighe, D., Bui, K.T., Venkatesha, V., Blinman, P.L., MacDougall H.G. & Vardy, J.L. Exploring assessment of balance using virtual reality in patients at risk of chemotherapy-induced peripheral neuropathy. Intern Med J; Advanced online publication 2022. doi: 10.1111/imj.15861

Zomerdijk N, Panozzo S, Mileshkin L, Yoong J, Nowak AK, Stockler MR, Philip J. Palliative care facilitates the preparedness of caregivers for thoracic cancer patients. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13716. doi: 10.1111/ecc.13716. Epub 2022 Sep 28. PMID: 36169179; PMCID: PMC9786261.

2020

Blinman, P., Martin, A., Jefford, M., Goldstein, D., Boadle, D., Morris, M., Tebbutt, N., Aiken, C., Harkin, A., Segelov, E. and Haydon, A., 2020. Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy for colon cancer. JNCI Cancer Spectrum.

Bui, K.T., Willson, M.L., Goel, S., Beith, J. & Goodwin, A. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database of Systematic Reviews 2020; (3), CD013538.

Chan, K.Y.C., Suen, M., Coulson, S. and Vardy, J.L., 2020. Efficacy of pelvic floor rehabilitation for bowel dysfunction after anterior resection for colorectal cancer: a systematic review. Supportive Care in Cancer, pp.1-15.

Chazan, G., Franchini, F., Alexander, M., Banerjee, S., Mileshkin, L., Blinman, P., Zielinski, R., Karikios, D., Pavlakis, N., Peters, S. and Lordick, F., 2020. Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO open, 5(6), p.e001090.

Cheng, Y.Y., Rath, E.M., Linton, A., Yuen, M.L., Takahashi, K. and Lee, K., 2020. The current understanding of asbestos-induced epigenetic changes associated with lung cancer. Lung Cancer: Targets and Therapy, 11, p.1.

Cheng, Y.Y., Yuen, M.L., Rath, E.M., Johnson, B., Zhuang, L., Yu, T.K., Aleksova, V., Linton, A., Kao, S., Clarke, C.J. and McCaughan, B.C., 2020. CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation. Frontiers in Oncology, 10.

Findlay, M., Rankin, N.M., Shaw, T., White, K., Boyer, M., Milross, C., De Abreu Lourenço, R., Brown, C., Collett, G., Beale, P. and Bauer, J.D., 2020. Best Evidence to Best Practice: Implementing an Innovative Model of Nutrition Care for Patients with Head and Neck Cancer Improves Outcomes. Nutrients, 12(5), p.1465.

Gutenkunst, S.L., Vardy, J.L., Dhillon, H.M. and Bell, M.L., 2021. Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems. Supportive Care in Cancer, 29(3), pp.1377-1386.

Joly, F., Castel, H., Tron, L., Lange, M. and Vardy, J., 2020. Potential effect of immunotherapy agents on cognitive function in cancer patients. JNCI: Journal of the National Cancer Institute, 112(2), pp.123-127.

Kiely, B.E. and Stockler, M.R., 2020. When should oncologists use the words hope and cure?. JNCI Cancer Spectrum.

Liu, J., Bui, K.T., Serafimovska, A., Kiely, B.E., Hui, M.N., Goodwin, A., McNeil, C.M., Costa, D.S., Butow, P. and Beith, J.M., 2020. CIFeR: A novel Clinician-lead Intervention to address Fear of cancer Recurrence (FCR) in breast cancer survivors.

Malalasekera, A., Dhillon, H.M., Shunmugasundaram, C., Blinman, P.L., Kao, S.C. and Vardy, J.L., 2020. Why do delays to diagnosis and treatment of lung cancer occur? A mixed methods study of insights from Australian clinicians. Asia?Pacific Journal of Clinical Oncology.

Moth, E.B., Blinman, P., Stefanic, N., Naganathan, V., Grimison, P., Stockler, M.R., Beale, P., Martin, A. and Kiely, B.E., 2020. Estimating survival time in older adults receiving chemotherapy for advanced cancer. Journal of geriatric oncology, 11(4), pp.617-625.

Moth, E.B., Kiely, B.E., Martin, A., Naganathan, V., Della-Fiorentina, S., Honeyball, F., Zielinski, R., Steer, C., Mandaliya, H., Ragunathan, A. and Blinman, P., 2020. Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences. Journal of geriatric oncology, 11(4), pp.626-632.

Nahm, S.H., Blinman, P., Butler, S., Tan, S.C. and Vardy, J., 2020. Factors associated with fear of cancer recurrence in breast and colorectal cancer survivors: A cross?sectional study of cancer survivors. Asia?Pacific Journal of Clinical Oncology.

Nowak, A.K., Lesterhuis, W.J., Kok, P.S., Brown, C., Hughes, B.G., Karikios, D.J., John, T., Kao, S.C., Leslie, C., Cook, A.M. and Pavlakis, N., 2020. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21(9), pp.1213-1223.

Scheinberg, T., Goodwin, A., Ip, E., Linton, A., Mak, B., Smith, D.P., Stockler, M.R., Strach, M.C., Tran, B., Young, A.L. and Zhang, A.Y., 2020. Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer. JCO Oncology Practice, pp.OP-20.

Scheinberg, T., Kench, J., Stockler, M., Mahon, K.L., Sebastian, L., Stricker, P., Joshua, A.M., Woo, H., Thanigasalam, R., Ahmadi, N. and Centenera, M.M., 2020. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ open, 10(1).

Shaikh, H., Bradhurst, P., Ma, L.X., Tan, S.Y.C., Egger, S.J. and Vardy, J.L., 2020. Body weight management in overweight and obese breast cancer survivors. Cochrane Database of Systematic Reviews, (12).

Sridhar, S.S., Blais, N., Tran, B., Reaume, M.N., North, S.A., Stockler, M.R., Chi, K.N., Fleshner, N.E., Liu, G., Robinson, J.W. and Mukherjee, S.D., 2020. Efficacy and Safety of nab-Paclitaxel vs paclitaxel on survival in patients with Platinum-refractory metastatic urothelial cancer: the Canadian Cancer Trials Group BL. 12 Randomized Clinical Trial. JAMA oncology, 6(11), pp.1751-1758.

Teng, C., Reuter, S.E., Blinman, P.L., Dhillon, H.M., Galettis, P., Proschogo, N., McLachlan, A.J. and Vardy, J.L., 2020. Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. Cancer Chemotherapy and Pharmacology, 86(4), pp.547-558.

Trejo, M.J., Bell, M.L., Dhillon, H.M. and Vardy, J.L., 2020. Baseline quality of life is associated with survival among people with advanced lung cancer. Journal of psychosocial oncology, 38(5), pp.635-641.

Vasista, A., Ryan, L., Naher, S., Moylan, E., Stockler, M.R., Wilcken, N. and Kiely, B.E., 2020. Survival and cardiac toxicity in patients with HER2?positive, metastatic breast cancer treated with trastuzumab in routine clinical practice. Asia?Pacific Journal of Clinical Oncology, 16(1), pp.34-38.

Vasista, A., Stockler, M.R., Martin, A., Lawrence, N.J. and Kiely, B.E., 2020. Communicating prognostic information: what do oncologists think patients with incurable cancer should be told?. Internal medicine journal, 50(12), pp.1492-1499.

2019

Ahmadzada, T., Lee, K., Clarke, C., Cooper, W.A., Linton, A., McCaughan, B., Asher, R., Clarke, S., Reid, G. and Kao, S., 2019. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer, 130, pp.35-41.

Alam N, Yu JQ, Beale P, Huq F. Dose and Sequence Dependent Synergism from the Combination of Oxaliplatin with Emetine and Patulin against Colorectal Cancer. Anticancer Agents Med Chem. 2019 Oct 21. doi: 10.2174/1871520619666191021112042. [Epub ahead of print]

Armstrong-Gordon E, Gnjidic D, McLachlan AJ, Hosseini B, Grant A, Beale PJ, Wheate NJ. Patterns of platinum drug use in an acute care setting: a retrospective study. J CANCER res Clin Oncol: 2018 Aug;144(8):1561-1568. doi: 10.1007/s00432-018-2669-6. Epub 2018 May 22.

Cao, C., Chakos, A., Guo, A., Park, J.J., Saghaie, T. and Blinman, P., 2019. Paradigm shift in local consolidative therapy for oligometastatic non-small cell lung cancer: a meta-analysis.

Chang, D.W., Bressel, M., Hansen, C., Blinman, P., Schofield, P. and Chua, B.H., 2019. Axillary dissection in sentinel lymph node positive breast cancer: Is the staging information worthwhile for patients?. Asia‐Pacific Journal of Clinical Oncology.

Collett, G.K., Durcinoska, I., Rankin, N.M., Blinman, P., Barnes, D.J., Anderiesz, C. and Young, J.M., 2019. Patients' experience of lung cancer care coordination: a quantitative exploration. Supportive Care in Cancer, 27(2), pp.485-493.

Daniels, B., Kiely, B.E., Tang, M. et al. Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015). BMC Cancer 19, 909 (2019). https://doi.org/10.1186/s12885-019-6126-y

Davis, I.D., Martin, A.J., Stockler, M.R., Begbie, S., Chi, K.N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W.E., Horvath, L.G. and Joshua, A.M., 2019. Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), pp.121-131.

Fogarty, G.B., Dolven-Jacobsen, K., Morton, R.L., Hruby, G., Nowak, A.K., Vardy, J.L., Drummond, K.J., Dhillon, H.M., Mandel, C., Scolyer, R.A. and Shivalingam, B., 2019. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs). International Journal of Radiation Oncology• Biology• Physics, 105(1), pp.S139-S140.

González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators.; Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. Epub 2018 Nov 16.

Hong, A.M., Fogarty, G.B., Dolven-Jacobsen, K., Burmeister, B.H., Lo, S.N., Haydu, L.E., Vardy, J.L., Nowak, A.K., Dhillon, H.M., Ahmed, T. and Shivalingam, B., 2019. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 37(33), pp.3132-3141.

Kiely BE, Stockler MR. Discussing Prognosis, Preferences, and End-of-Life Care in Advanced Cancer: We Need to Speak. JAMA Oncol. 2019;5(6):788-789. doi:10.1001/jamaoncol.2019.0291

Lange, M., Joly, F., Vardy, J., Ahles, T., Dubois, M., Tron, L., Winocur, G., De Ruiter, M.B. and Castel, H., 2019. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Annals of Oncology, 30(12), pp.1925-1940.

Linton, A., Blinman, P., Kao, S. and van Zandwijk, N., 2019. Patterns of care and survival of older patients with malignant pleural mesothelioma. Journal of geriatric oncology, 10(4), pp.573-576.

Livingstone, A., Agarwal, A., Stockler, M.R., Menzies, A.M., Howard, K. and Morton, R.L., 2019. Preferences for immunotherapy in melanoma: a systematic review. Annals of surgical oncology, pp.1-14.

Lord SJ, Kiely BE, Pearson S, et al. Metastatic breast cancer incidence, site and survival in Australia, 2001-2016: a population-based health record linkage study protocol. BMJ Open 2019;9:e026414. doi: 10.1136/bmjopen-2018-026414

Mahon, K.L., Qu, W., Lin, H.M., Spielman, C., Cain, D., Jacobs, C., Stockler, M.R., Higano, C.S., de Bono, J.S., Chi, K.N. and Clark, S.J., 2019. Serum free methylated glutathione S-transferase 1 DNA levels, survival, and response to docetaxel in metastatic, castration-resistant prostate cancer: post hoc analyses of data from a phase 3 trial. European urology, 76(3), pp.306-312.

Martin, A.J., Dhillon, H.M., Vardy, J.L., Dalziell, R.A., Choy, B., Fernández-Peñas, P., Dixon, A., Renton, C., St George, G., Chinniah, N. and Halliday, G.M., 2019. Neurocognitive Function and Quality of Life Outcomes in the ONTRAC Study for Skin Cancer Chemoprevention by Nicotinamide. Geriatrics, 4(1), p.31.

Mocellin, S., Goodwin, A. and Pasquali, S., 2019. Risk‐reducing medications for primary breast cancer: a network meta‐analysis. Cochrane Database of Systematic Reviews, (4).

Moth EB, Blinman P, Stefanic N, Naganathan V, Grimison P, Stockler MR, Beale P, Martin A, Kiely BE. Estimating survival time in older adults receiving chemotherapy for advanced cancer. J Geriatr Oncol. 2019 Sep 6. pii: S1879-4068(19)30216-4. doi: 10.1016/j.jgo.2019.08.013.

Moth EB, Kiely BE, Stefanic N, Naganathan V, Martin A, Grimison P, Stockler MR, Beale P, Blinman P. Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. J Geriatr Oncol. 2019 Mar;10(2):210-215. doi: 10.1016/j.jgo.2018.11.004. Epub 2018 Nov 28.

Moth EB, Kiely BE, Stefanic N, Naganathan V, Martin A, Grimison P, Stockler MR, Beale P, Blinman P. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. 1.

Shafiei M, Yoon R, McLachlan A, Boddy A, Beale P, Blinman P. Pharmacokinetics of Anticancer Drugs Used in Treatment of Older Adults With Colorectal Cancer: A Systematic Review. Ther Drug Monit. 2019 Oct;41(5):553-560. doi: 10.1097/FTD.0000000000000635.

Shepherd HL, Geerligs L, Butow P, Masya L, Shaw J, Price M, Dhillon HM, Hack TF, Girgis A, Luckett T, Lovell M, Kelly B, Beale P, Grimison P, Shaw T, Viney R, Rankin NM. The Elusive Search for Success: Defining and Measuring Implementation Outcomes in a Real-World Hospital Trial. Front Public Health. 2019 Oct 18;7:293. doi: 10.3389/fpubh.2019.00293. eCollection 2019.

Sutherland, S., Meiser, B., Kaur, R., Mitchell, G., Kirk, J., Peate, M., Tim Wong, W.K. and Goodwin, A., 2019. Assessing the medical workforces perceived barriers to the prescription of risk‐reducing medication for women at high‐risk of breast cancer. The breast journal, 25(1), pp.34-40.

Sweeney, C., Martin, A.J., Zielinski, R.R., Thomson, A., Tan, T.H., Sandhu, S.K., Reaume, M.N., Pook, D.W., Parnis, F., North, S.A. and McDermott, R., 2019. Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. DOI: 10.1200/JCO.2019.37.18_suppl.LBA2 Journal of Clinical Oncology 37, no. 18_suppl

Tan, S.Y., Turner, J., Kerin-Ayres, K. et al. Health concerns of cancer survivors after primary anti-cancer treatment. Support Care Cancer 27, 3739-3747 (2019). https://doi.org/10.1007/s00520-019-04664-w

Tang, M., Schaffer, A., Kiely, B.E. et al. Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016). Br J Cancer 121, 904-911 (2019). https://doi.org/10.1038/s41416-019-0612-5

Vardy, J.L., Chan, R.J., Koczwara, B., Lisy, K., Cohn, R.J., Joske, D., Dhillon, H.M. and Jefford, M., 2019. Clinical Oncology Society of Australia position statement on cancer survivorship care. Australian journal of general practice, 48(12), p.833.

Vardy, J.L., Stouten-Kemperman, M.M., Pond, G., Booth, C.M., Rourke, S.B., Dhillon, H.M., Dodd, A., Crawley, A. and Tannock, I.F., 2019. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain imaging and behavior, 13(1), pp.15-26.

Warby, A., Dhillon, H.M., Kao, S. and Vardy, J.L., 2019. A survey of patient and caregiver experience with malignant pleural mesothelioma. Supportive Care in Cancer, 27(12), pp.4675-4686.

Warby, A., Dhillon, H.M., Kao, S. and Vardy, J.L., 2019. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma. Supportive Care in Cancer, 27(9), pp.3509-3519.

Whitford, H.S., Kalinowski, P., Schembri, A., Grimison, P., Stockler, M., Martin, A., Toner, G.C., Davis, I.D., Maruff, P. and Olver, I.N., 2019. The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer. Supportive Care in Cancer, pp.1-11.

Wilson, B.E., Mok, K., Kiely, B.E., Nguyen, R. and Moylan, E. (2019), Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer. Intern Med J, 49: 1438-1442. doi:10.1111/imj.14629

Zaheed, M., Wilcken, N., Willson, M.L., O'Connell, D.L. and Goodwin, A., 2019. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database of Systematic Reviews, (2).

Zhang, A.Y., Toner, G.C., Lawrence, N.J., Stockler, M.R., Martin, A.J., Ford, K., Stevanovic, A.G., Wyld, D., Walpole, E.T., Troon, S. and Hanning, F.J., 2019. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). DOI: 10.1200/JCO.2019.37.7_suppl.TPS539 Journal of Clinical Oncology 37, no. 7_suppl (March 01, 2019) TPS539-TPS539.

Medical Oncology Research

Selected Grants

Our Publications

2023

Medical Oncology Research

Medical Oncology Research

Our Organisation

Make a Donation

Our Hospitals

Right to Information

Plans

Publications

Quick Links